Results for: Out-of-Pocket Costs

A study has found that two years after biosimilars became available in the U.S., a higher proportion of patients using brand-name biologics were paying out-of-pocket costs, which were also, on average, 12% higher than before. In addition, patients who used biosimilars often did not pay lower out-of-pocket costs than those who were given brand-name biologic medicines. The findings suggest that the arrival of biosimilars has failed to fully deliver on their promise of lower costs for patients.

Starting in 2025, Medicare Advantage and Part D plans will undergo significant changes. This article provides a summary of three major changes: the elimination of sales incentives for agents and brokers, the requirement for plans to send personalized notifications about unused supplemental benefits, and the cap on out-of-pocket costs for covered Part D drugs.